메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

알라마 바이오사이언스, 알츠하이머 협회 국제학술대회(AAIC)에서 획기적인 뇌 유래 pTau 데이터 공개

[ 메디채널 김갑성 기자 ] 신경퇴행성 질환 바이오마커 연구의 새로운 지평 - 30개 이상의 포스터 및 프레젠테이션 통해 공개 프리몬트, 캘리포니아, 2025년 7월 28일 -- 정밀 단백체학을 기반으로 질병의 조기 진단을 선도하고 있는 알라마 바이오사이언스(Alamar Biosciences)가 자사의 NULISA™ 플랫폼 관련 데이터를 7월 27일부터 31일까지 캐나다 토론토에서 열리는 알츠하이머 협회 국제학술대회(Alzheimer's Association International Conference, AAIC)에서 30건 이상의 학술 세션과 포스터 발표를 통해 공개한다고 밝혔다. NULISA 플랫폼은 신경퇴행성 질환 진단 및 모니터링을 위한 바이오마커 검출 분야에서 감도, 특이성, 다중 분석 능력 측면에서 새로운 기준을 제시할 것으로 기대된다. 올해 AAIC에서는 NULISA를 사용하여 뇌유래 pTau와 120개 이상의 주요 중추신경계(CNS) 질환 관련 단백질에 대한 강력한 임상 데이터가 처음으로 공개된다. 이는 알츠하이머병 및 관련 신경퇴행성 질환의 조기 발견과 치료 모니터링을 가속화할 수 있는 중대한 성과로 평가된다.
- 김갑성 기자
- 2025-07-28 20:12
Herbalgy x TEEMTONEfai Make a Groundbreaking Crossover Debut Cool Vibes to Welcome Herbalgy Trophy

A Summer Cool-Off: Exclusive Mint Gelato x Icy Touch-Cool Download high-resolution images: https://cutt.ly/arP67T4q HONG KONG, July 28, 2025 -- To celebrate its 25th anniversary, Herbalgy is unveiling a bold new image by teaming up with local creative ice cream brand TEEMTONEfai to launch the limited-time "So Cool Summer Pop-Up Campaign". This cool collaboration marks a refreshing milestone for Herbalgy. As the title sponsor of the highly anticipated international football match – the Herbalgy Trophy, set to take place on July 31 at Kai Tak Sports Stadium, Herb
- 황정호 기자
- 2025-07-28 19:29
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

- This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China.- XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List.- Results from the BENCH study
- 김갑성 기자
- 2025-07-28 18:49
Interventional Robot's RCT Research Published in JNIS, a Leading Journal in Neurointervention!

SHANGHAI, July 28, 2025 -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital) in collaboration with Professor Sun Jun (Wenzhou Central Hospital), Professor Chen Wenhuo (Zhangzhou Municipal Hospital of Fujian Province), and Professor Cheng Guangsen (Zhuhai People's Hospital)—have been officially published in the Journal of NeuroInterventional Surgery (JNIS). This milestone marks the first time a China-developed vascular-interventional robot has gained recognition from a premier inte
- 김갑성 기자
- 2025-07-28 18:35
Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced Efficiency, Ease of Use, and Extended Shelf Life

SUNNYVALE, Calif., July 28, 2025 -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iteration of the innovative device delivers significant enhancements, including an extended shelf life, improved ease of use, and streamlined preparation, directly addressing critical feedback from physician users. The highly anticipated Sniper G3 features a 24-month shelf life, doubling the longevity of its predecessor. This improvement offers greater invent
- 김갑성 기자
- 2025-07-28 18:00
Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phase 3 Study for Reducing Abdominal Subcutaneous Fat

CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, multicenter, pivotal Phase 3 study. Subject recruitment is expected to begin in the U.S. and Canada in Q3 2025. CBL-514 is the first 505(b)(1) investigational drug with FDA clearance to proceed with a Phase 3 study for the proposed indication of "Reduction of Abdominal Subcutaneous Fat." Caliway also plans to submit regulatory applications for its second global pivotal Phase 3 study, SUPREME-02, in the U.S., Canada, and Australi
- 김갑성 기자
- 2025-07-28 17:51
Precision Orthopedic Surgery in Asia: Addressing Regional Needs through Academic Collaboration with MOA and Aclub

TAIPEI, July 28, 2025 -- The Malaysian Orthopedic Association (MOA), Aclub Taiwan, and A Plus Biotechnology Corporation Limited will co-host a high-level academic conference on August 3, 2025, at Sunway Medical Centre in Kuala Lumpur, bringing together orthopedic professionals from across Asia to explore the latest advances in personalized, minimally invasive orthopedic surgery. The event will feature both in-person and online participation options. As Asia's active population grows and patient expectations evolve, the demand for personalized, minimally invasive orthopedic solu
- 김갑성 기자
- 2025-07-28 17:32
HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore

SINGAPORE, July 28, 2025 -- In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C. This marks a significant step towards the Educate, Test, Treat! (ETT) initiative, launched in 2022 with the funding support of Gilead Sciences. Witnessed by Mdm Rahayu Mahza
- 김갑성 기자
- 2025-07-28 16:11
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis

KOLKATA, India, July 28, 2025 -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated with Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Manipal Hospital Dhakuria, under the expertise of Dr. Ashutosh Daga, Medical Oncologist, and Dr. Sagnik Ray, Surgical Oncologist. The 12-hour long procedure adds a milestone in cancer care treatment. The sexagenarian was initially taken to another hospital where she was misdiagnosed as a case of chronic liver failure with ascites
- 김갑성 기자
- 2025-07-28 15:20
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

[ 메디채널 김갑성 기자 ] CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharmaceutical DAEJEON, South Korea, July 28, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI® (code name: ALT-L9), a bi
- 김갑성 기자
- 2025-07-28 14:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-01_MON

2025-08-31_SUN

2025-08-30_SAT

Global Trade Review Announces GTR Asia 2025 in Singapore - the premier platform for the trade community in the Asia Pacific region - hits over 1,500 registration for September 2-3 23:39

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 01일 09시 00분